Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Second Spring? Coverage Expansion Fuels Big Pharma China Growth But '4+7' Impact Lingers

Executive Summary

AstraZeneca, Novartis and Roche deliver north of 20% sales growth in China again, driven by expanded reimbursement coverage and new product launches, but some clouds are on the horizon over falling sales due to the impact of the expanding “4+7” centralized procurement scheme.

You may also be interested in...



10 Commercial Trends To Watch In China in 2020

2019 will be remembered as a banner year for international drug makers as many grew at phenomenal rates in China, despite expansion of the “4+7” centralized procurement scheme and steep price cuts in exchange for reimbursement. As the government continues to emphasize affordability for cancer drugs and major anti-infectives, competition is heating up quickly and immune-oncology alone has seen six PD-1s elbowing each other for market share.

Sun Allies With AZ To Drive China Oncology Push

India's Sun Pharma joins hands with AstraZeneca to commercialize certain 'ready to use' oncology therapies in China, hoping to capitalize on the UK firm’s strong position in this market.

Amgen Joins China Oncology Market Race With $2.7bn BeiGene Stake

As China embraces novel new drugs, oncology is quickly becoming the biggest opportunity for pharma to drive growth in this market. Amgen is the latest to jump on board through the purchase of a significant stake in BeiGene.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1122113

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel